Peptide Finder US
PeptideFinder
Find a ClinicTreatment GoalsPeptidesBlog
For Clinics
Compounded SemaglutideSemaglutideOzempicFDAGLP-1Weight Loss

Compounded Semaglutide in 2026: What Changed After the FDA Shortage Ended

Peptide Finder EditorialMay 1, 20269 min read

For two years, compounded semaglutide was widely available to US patients through telehealth clinics, filling the gap left by severe Ozempic and Wegovy shortages. In late 2024 and into 2025, the FDA declared the semaglutide shortage over and began enforcement actions against compounding pharmacies continuing to produce it. If you relied on compounded semaglutide - or are just entering the market - here is what the current landscape looks like.

What happened: the shortage and its end

When Ozempic demand surged in 2022-2023, Novo Nordisk's manufacturing capacity could not keep up. The FDA placed semaglutide on its drug shortage list, which triggered a specific exemption allowing 503A and 503B compounding pharmacies to produce compounded semaglutide under shortage rules.

The shortage created a massive telehealth boom. Dozens of legitimate physician-supervised programs emerged, along with grey-market vendors selling unlicensed versions. Patients who could not access or afford branded Ozempic or Wegovy found compounded alternatives at $150-400/month.

In late 2024, the FDA concluded Ozempic and Wegovy supply had sufficiently recovered and removed semaglutide from the shortage list. This triggered several enforcement actions:

  • 503B outsourcing facilities (large-scale compounders) were told to stop producing compounded semaglutide entirely
  • 503A pharmacies (patient-specific compounders) can still produce compounded semaglutide under certain circumstances, specifically for patients with a documented clinical need not met by the branded product
  • Enforcement of grey-market vendors selling unlicensed "semaglutide" increased significantly

---

What is still legally available in 2026

Compounded semaglutide from 503A pharmacies remains available, but the landscape has narrowed:

  • A valid prescription from a licensed physician is required
  • The physician must have a legitimate clinical rationale for compounded vs. branded semaglutide (e.g., the patient cannot tolerate the branded formulation, has an allergy to an excipient, or needs a different dose or delivery method)
  • The compounding pharmacy must be properly licensed and operating within 503A rules

Many legitimate telehealth clinics still offer compounded semaglutide through 503A partnerships. The pathway is not closed - it is just more restricted than it was during the shortage.

Branded options with better access:

  • Novo Nordisk has significantly expanded production. Ozempic and Wegovy are generally available at pharmacies, though insurance coverage for weight loss (Wegovy) remains inconsistent.
  • Tirzepatide (Mounjaro/Zepbound) has filled significant demand. Zepbound's weight loss data are actually superior to Wegovy in head-to-head comparisons. Compare semaglutide vs. tirzepatide.

---

What this means for current patients

If you are currently on compounded semaglutide through a legitimate clinic:

  • Your program is likely still intact. Ask your clinic directly whether they are using 503A compounding and what their current pharmacy relationship is.
  • Clinics operating properly have adapted their pharmacy sourcing. This is routine for compliant operations.
  • If your clinic cannot answer basic questions about where your medication is compounded, that is a red flag.

If you are starting fresh and looking for GLP-1 therapy:

  • Telehealth clinics remain the fastest route to evaluation and prescription
  • Ask whether you would receive branded or compounded medication, and from which pharmacy
  • Compare costs: branded Wegovy with insurance may be cost-competitive with compounded alternatives depending on your plan
  • Consider tirzepatide (Zepbound) - it is FDA-approved for weight management and has shown greater weight loss in trials

---

What to ask your clinic

Before starting any GLP-1 program, ask:

  1. 1Will I receive branded or compounded medication?
  2. 2If compounded - which 503A pharmacy fills the prescription?
  3. 3Is that pharmacy accredited (e.g., PCAB accreditation)?
  4. 4What is the dosing schedule and titration plan?
  5. 5What monitoring is included and how often will I have follow-up contact?

A clinic that cannot answer questions 1-3 clearly should be viewed with caution.

---

Finding a GLP-1 clinic in 2026

Peptide Finder lists physician-supervised GLP-1 clinics operating within the current regulatory framework:

Browse by state: California - Texas - Florida - New York - Georgia - browse all states.

Related: Where to buy peptides legally in the US - Compounded peptides: what to know

Ready to find a clinic?

Browse physician-supervised peptide clinics across the US. Compare consultation type, services, and telehealth availability.

Browse Clinics

Related Guides

Keep researching

View all guides
OzempicGLP-1

Ozempic Near Me: How to Find a Legitimate GLP-1 Prescriber in Your State

Searching 'Ozempic near me'? Here is how to find a legitimate GLP-1 prescriber in your state - and how to tell a real clinic from a pill mill.

Weight LossGLP-1

GLP-1 Clinic Near Me: How to Find One in Your State

GLP-1 medications like semaglutide and tirzepatide are now available through hundreds of physician-supervised clinics across the US. Finding the right one requires knowing what to look for.

Weight LossGLP-1

Semaglutide vs Tirzepatide: What to Ask Your Doctor

Semaglutide and tirzepatide are both FDA-approved for weight management, but they work differently and cost differently. Here is what to understand before talking to your doctor.